The management of patients with early Parkinson's disease.
A major problem in the management of early Parkinson's disease is to choose the first medication to prescribe. This decision should rely on the level of available clinical evidence, largely based, at least for efficacy, on the results of randomised clinical trials. Safety and costs are also crucial to consider. Other factors like for example pathophysiological concepts, individual experience, marketing pressure, socio-economical environment, patients needs and expectations have, however, also their own influence. Levodopa is efficacious and cheap, but induces long-term motor complications. The early use of dopamine agonists is more and more frequently promoted, because large prospective L-dopa-controlled trials demonstrated that this strategy reduces the risk of such long-term complications. Integrating individual clinical expertise to the best available external clinical evidence (evidence-based medicine) is the best strategy in making decisions about the care of individual patients.
Rascol
O
O
Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, Toulouse University Hospital, Toulouse, France. rascol@cict.fr
Payoux
P
P
Ferreira
J
J
Brefel-Courbon
C
C
D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics
D000978:Antiparkinson Agents